Study on new strategy of glioblastoma treatment by molecular targeted anti-cancer hybrid peptide
Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
Date (from‐to) : 2014/04 -2017/03
Author : Kawakami Koji; HORIBE TOMOHISA; KOHNO MASAYUKI; KURIHARA RYOUSUKE; SETO KAHORI; ARONGGAOWA
We focused on the IL-13 receptor alpha 2 (IL13Ralpha2), which plays critical and important roles in glioblastoma cells, and performed the screening binding peptide to the receptor using T7 phage display system. We successfully selected one candidate peptide binding specifically to IL13Ralpha2, and designed IL13Ra2-lytic hybrid peptide by conjugation with lytic type peptide against cancer membrane. It was found that IL13Ra2-lytic had effective cytotoxic activity against glioblastoma cell lines which express IL13Ralpha2, and the peptide had also anti-tumor activity in vivo. These results suggest that hybrid peptide designed in this study may also new candidate for the development of glioblastoma treatment in the future.